Bio-Rad Laboratories, Inc. (BIO) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 14 analysts13.9% Below Target
BIO trades 13.9% below Wall Street's consensus target of $321.67.
Current Price$282.44
Average Target$321.67
Target
Current
Low$310.00
Median$320.00
High$335.00
Analyst Target Range
Forward P/E31.2x
(Growth Premium)
PEG Ratio—
Implied Growth+44.4%
(High Growth)
Analyst Spread7.8%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes BIO achieves its forward estimates and maintains a stable P/E multiple of 31.2x. This scenario reflects the blended consensus of 14 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
BIO Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Bio-Rad Laboratories, Inc. (BIO) has a Wall Street consensus price target of $321.67, based on estimates from 14 covering analysts. With the stock currently trading at $282.44, this represents a potential upside of +13.9%. The company has a market capitalization of $7.63B.
Analyst price targets range from a low of $310.00 to a high of $335.00, representing a 8% spread in expectations. The median target of $320.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BIO trades at a trailing P/E of 10.1x and forward P/E of 31.2x. Analysts expect EPS to grow +44.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+35.9%
Industry Consensus
Avg Forward P/E
30.2x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 TMOThermo Fisher Scientific Inc. | $172.7B | $464.61 | $599.70 | +29.1% | Buy | 18.7x | 42 |
 DHRDanaher Corporation | $125.4B | $177.17 | $230.89 | +30.3% | Buy | 21.0x | 43 |
 BRKRBruker Corporation | $8.7B | $57.23 | $47.67 | -16.7% | Buy | 27.0x | 32 |
 RGENRepligen Corporation | $7.4B | $132.02 | $158.67 | +20.2% | Buy | 65.9x | 24 |
 CRLCharles River Laboratories International, Inc. | $8.9B | $185.00 | $214.14 | +15.8% | Buy | 16.7x | 37 |
 IDXXIDEXX Laboratories, Inc. | $44.6B | $562.09 | $747.50 | +33.0% | Buy | 38.3x | 22 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 QGENQiagen N.V. | $7.6B | $36.95 | $45.17 | +22.2% | Hold | 15.2x | 30 |
 AZTAAzenta, Inc. | $1.1B | $23.31 | $44.50 | +90.9% | Buy | 52.0x | 12 |
 NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
BIO — Frequently Asked Questions
Quick answers to the most common questions about buying BIO stock.
What is the BIO stock price target for 2026?
Bio-Rad Laboratories, Inc. (BIO) has a consensus 12-month price target of $321.67, implying 13.9% upside from $282.44. The 14 analysts covering BIO see moderate appreciation potential.
Is BIO a buy, sell, or hold?
BIO has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $321.67 implies 13.9% upside from current levels.
Is BIO stock overvalued or undervalued?
BIO trades at a forward P/E of 31.2382x, representing a moderate valuation. With analysts targeting $321.67 (13.9% implied move), the stock appears reasonably valued with upside.
How high can BIO stock go?
The most bullish Wall Street analyst has a price target of $335 for BIO, while the most conservative target is $310. The consensus of $321.67 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover BIO stock?
BIO is moderately covered, with 14 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 7 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the BIO stock forecast?
The 12-month BIO stock forecast based on 14 Wall Street analysts shows a consensus price target of $321.67, with estimates ranging from $310 (bear case) to $335 (bull case). The median consensus rating is "Buy".
What is BIO's forward P/E ratio?
BIO trades at a forward P/E ratio of 31.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 10.1x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy BIO stock?
Wall Street analysts are optimistic on BIO, with a "Buy" consensus rating and $321.67 price target (13.9% upside). 8 of 14 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do BIO price targets vary so much?
BIO analyst price targets range from $310 to $335, a 8% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $321.67 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare